Your browser doesn't support javascript.
loading
In utero exposure to antiretroviral drugs and pregnancy outcomes: Analysis of the French ANRS pharmacovigilance database.
Saint-Lary, Laura; Diallo, Alpha; de Monteynard, Laure-Amélie; Paul, Christelle; Marchand, Lucie; Tubiana, Roland; Warszawski, Josiane; Mandelbrot, Laurent; Rekacewicz, Claire; Petrov-Sanchez, Ventzislava; Faye, Albert; Sibiude, Jeanne; Dabis, François; Sommet, Agnès; Leroy, Valériane.
Afiliación
  • Saint-Lary L; CERPOP, Inserm, Université de Toulouse, Université Paul Sabatier III, Toulouse, France.
  • Diallo A; Clinical Trial Safety and Public Health, ANRS, Paris, Île-de-France, France.
  • de Monteynard LA; International Research and Collaboration Unit, ANRS, Paris, Île-de-France, France.
  • Paul C; Clinical Trial Safety and Public Health, ANRS, Paris, Île-de-France, France.
  • Marchand L; Clinical and Therapeutic Research on HIV and Hepatitis Unit, ANRS, Paris, Île-de-France, France.
  • Tubiana R; University Hospital Pitié Salpêtrière Infectious and Tropical Diseases Service, Sorbonne Université, Inserm UMR-1136 Pierre Louis Institute of Epidemiology and Public Health, Paris, Île-de-France, France.
  • Warszawski J; Hospital Louis-Mourier, Obstetrics-Gynecology Department, Colombes CESP, Inserm U1018 Université Paris Diderot Risks in Pregnancy University Department, Colombes, Île-de-France, France.
  • Mandelbrot L; Hospital Louis-Mourier, Service de Gynécologie-Obstétrique, Institut national de la santé et de la recherche médicale Iame-U1137, Université Paris-Diderot, Colombes, Île-de-France, France.
  • Rekacewicz C; International Research and Collaboration Unit, ANRS, Paris, Île-de-France, France.
  • Petrov-Sanchez V; Clinical and Therapeutic Research on HIV and Hepatitis Unit, ANRS, Paris, Île-de-France, France.
  • Faye A; Robert-Debré Mother-Child University Hospital Division of Paediatric Medicine, Université Paris 7 Denis Diderot, Sorbonne Paris Cité, Inserm U1123, Paris, Île-de-France, France.
  • Sibiude J; Maternité Port-Royal, Département Hospitalier Universitaire Risques et Grossesse, Inserm U1018, Paris, Île-de-France, France.
  • Dabis F; Clinical Trial Safety and Public Health, ANRS, Paris, Île-de-France, France.
  • Sommet A; Inserm U1219, University of Bordeaux, ISPED, Bordeaux Population Health Research Center, Bordeaux, France.
  • Leroy V; CERPOP, Inserm, Université de Toulouse, Université Paul Sabatier III, Toulouse, France.
Br J Clin Pharmacol ; 88(3): 942-964, 2022 03.
Article en En | MEDLINE | ID: mdl-34505718
ABSTRACT

AIMS:

In 2018, 1.07 million pregnant women received antiretroviral drugs, raising whether this affects pregnancy outcomes. We assessed the adverse pregnancy outcomes associated with prenatal antiretroviral drug exposure, notified to the French ANRS pharmacovigilance system.

METHODS:

An exhaustive case report series has been performed using the ANRS pharmacovigilance database. All ANRS-sponsored HIV clinical research studies using antiretroviral drugs either in pregnant women or women of childbearing age were eligible from 2004 to 2019. We analysed the following pregnancy

outcomes:

abortion, ectopic pregnancy, stillbirth, prematurity (<37 weeks of gestational age), low birth weight (<2500 g) and congenital abnormalities. A logistic regression was performed to assess the odds ratio (OR) for each outcome separately (if occurrence >50) compared to the outcome observed when exposed to non-nucleoside-reverse-transcriptase-inhibitor (NNRTI)-based regimen as the reference.

RESULTS:

Among the 34 studies selected, 918 deliveries occurred, of whom 88% had pregnancy outcomes documented. Pregnant women were mainly exposed to PI (n = 387, 48.6%), NNRTI (n = 331, 41.5%) and INI-based combinations (n = 40, 5.0%, 18 on dolutegravir). Compared to NNRTI-based combinations, there was no significant association observed with exposure to other antiretroviral combination for spontaneous abortion, prematurity or low birth weight, except an increased risk of low birth weight in new-born exposed to exclusive nucleoside-reverse-transcriptase-inhibitor (NRTI) combinations (n = 4; OR 7.50 [1.49-37.83]).

CONCLUSIONS:

Our study, mainly based on protease inhibitor (PI) and NNRTI-based regimens, is overall reassuring on the risk of adverse pregnancy outcomes, except for NRTI which should be interpreted cautiously (small number, indication bias). In this study, the number of integrase inhibitor (INI)-based combinations was too low to draw any conclusions.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Infecciones por VIH / Inhibidores de Integrasa VIH / Fármacos Anti-VIH Límite: Female / Humans / Pregnancy Idioma: En Revista: Br J Clin Pharmacol Año: 2022 Tipo del documento: Article País de afiliación: Francia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Infecciones por VIH / Inhibidores de Integrasa VIH / Fármacos Anti-VIH Límite: Female / Humans / Pregnancy Idioma: En Revista: Br J Clin Pharmacol Año: 2022 Tipo del documento: Article País de afiliación: Francia
...